NDMA urges "substantial evidence" standard of judicial review for FDA rulemaking.
This article was originally published in The Tan Sheet
Executive Summary
"SUBSTANTIAL EVIDENCE" STANDARD OF JUDICIAL REVIEW FOR FDA RULEMAKING is urged by the Nonprescription Drug Manufacturers Association in written testimony to the House Commerce Committees/health subcommittee. The testimony was part of a May 1-2 hearing on FDA reform legislation.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: